带有双级联放大器的混合纳米强化器用于质瘤联合干预治疗治疗
Zixuan Ye1, Ji Liu1, Yanyan Liu1
1Department of Pharmaceutics, State Key Laboratory of Nature Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China.
概括
这项研究引入了一种新的纳米粒子系统 (CFpAD),通过克服瘤障碍和改善药物输送来增强质瘤化疗. 该系统使用级联放大方法产生反应性氧物种,导致显著的癌细胞死亡.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- 由于化疗中的挑战,包括瘤向和透率差,质瘤的预后不好.
- 瘤微环境对有效的药物输送和质瘤治疗的治疗结果构成重大障碍.
研究的目的:
- 设计和评估一个核心外结构级联增强混合催化纳米电源 (CFpAD) 克服质瘤的治疗障碍.
- 通过改善瘤积累,透和协同治疗效果来提高质瘤化疗的疗效.
主要方法:
- 开发封装DM1的CFpAD纳米粒子,使用NIR激光穿透血脑屏障 (BBB).
- CFpAD触发了一种级联反应,释放金纳米粒子 (GOx) 和氧化铁纳米粒子 (FNP),产生活性氧物种 (ROS).
- 化学疗法,干预光热疗法 (IPTT) 和放射疗法 (RT) 与饥饿治疗的结合.
主要成果:
- 尼尔射线激光增强了BBB透和CFpAD的瘤积累.
- 通过级联放大,CFpAD触发了ROS的产生,诱导了瘤细胞的亡.
- 由于DM1化疗,IPTT,RT和饥饿治疗的协同效应,观察到质瘤细胞活力的显著下降.
- 金纳米颗粒减少了与癌症相关的纤维细胞 (CAF) 和细胞外基质 (ECM) 分泌,改善了CFpAD的透.
结论:
- 开发的CFpAD系统证明了有效克服质瘤治疗障碍,包括瘤向和透能力差.
- 级联放大,饥饿治疗,IPTT和RT的协同组合显示出卓越的抗瘤疗效.
- CFpAD代表了一种有前途的治疗系统,用于治疗质瘤,增强瘤透率和显著的抗瘤作用.
更多相关视频
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
2.3K
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.5K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...